Pliant Therapeutics, Inc. Common Stock (PLRX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLRX trades at $1.19 with a market cap of $73.07M and a P/E ratio of -0.50. PLRX moved +5.22% today. Year to date, PLRX is -6.61%; over the trailing twelve months it is -12.41%. Its 52-week range spans $1.09 to $16.10. Analyst consensus is neutral with an average price target of $2.67. Rallies surfaces PLRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pliant Therapeutics Posts 4 Responders with 71% Tumor Reduction, Q2 Phase Ib Planned: Early Phase I data for oral integrin inhibitor PLN-101095 showed four responders (three PRs, one CR) with an average 71% tumor reduction at ≥1,000 mg BID and manageable mild-to-moderate rash. Pliant will start Phase Ib pembrolizumab expansion in Q2 for NSCLC, high TMB and RCC backed by $211M cash runway.
| Metric | Value |
|---|---|
| Price | $1.19 |
| Market Cap | $73.07M |
| P/E Ratio | -0.50 |
| EPS | $-2.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.10 |
| 52-Week Low | $1.09 |
| Volume | 906 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-149.34M |
| Gross Margin | 0.00% |
5 analysts cover PLRX: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.67.